Ralph Peterli1, Bettina Karin Wölnerhanssen2,3, Thomas Peters4, Diana Vetter5, Dino Kröll6, Yves Borbély6, Bernd Schultes7, Christoph Beglinger2, Jürgen Drewe8, Marc Schiesser9, Philipp Nett6, Marco Bueter5. 1. Department of Surgery, St Claraspital, Basel, Switzerland. 2. Department of Clinical Research, St Claraspital, Basel, Switzerland. 3. Department of Biomedicine, University Hospital of Basel, Basel, Switzerland. 4. Department of Internal Medicine, St Claraspital, Basel, Switzerland. 5. Department of Visceral and Transplantation Surgery, University Hospital, Zürich, Switzerland. 6. Department of Surgery, University Hospital, Bern, Switzerland. 7. Swiss Medical and Surgical Center, St Gallen, Switzerland. 8. Department of Pharmacology and Toxicology, University Hospital, Basel, Switzerland. 9. Department of Surgery, Kantonsspital, St Gallen, Switzerland.
Abstract
Importance: Sleeve gastrectomy is increasingly used in the treatment of morbid obesity, but its long-term outcome vs the standard Roux-en-Y gastric bypass procedure is unknown. Objective: To determine whether there are differences between sleeve gastrectomy and Roux-en-Y gastric bypass in terms of weight loss, changes in comorbidities, increase in quality of life, and adverse events. Design, Setting, and Participants: The Swiss Multicenter Bypass or Sleeve Study (SM-BOSS), a 2-group randomized trial, was conducted from January 2007 until November 2011 (last follow-up in March 2017). Of 3971 morbidly obese patients evaluated for bariatric surgery at 4 Swiss bariatric centers, 217 patients were enrolled and randomly assigned to sleeve gastrectomy or Roux-en-Y gastric bypass with a 5-year follow-up period. Interventions: Patients were randomly assigned to undergo laparoscopic sleeve gastrectomy (n = 107) or laparoscopic Roux-en-Y gastric bypass (n = 110). Main Outcomes and Measures: The primary end point was weight loss, expressed as percentage excess body mass index (BMI) loss. Exploratory end points were changes in comorbidities and adverse events. Results: Among the 217 patients (mean age, 45.5 years; 72% women; mean BMI, 43.9) 205 (94.5%) completed the trial. Excess BMI loss was not significantly different at 5 years: for sleeve gastrectomy, 61.1%, vs Roux-en-Y gastric bypass, 68.3% (absolute difference, -7.18%; 95% CI, -14.30% to -0.06%; P = .22 after adjustment for multiple comparisons). Gastric reflux remission was observed more frequently after Roux-en-Y gastric bypass (60.4%) than after sleeve gastrectomy (25.0%). Gastric reflux worsened (more symptoms or increase in therapy) more often after sleeve gastrectomy (31.8%) than after Roux-en-Y gastric bypass (6.3%). The number of patients with reoperations or interventions was 16/101 (15.8%) after sleeve gastrectomy and 23/104 (22.1%) after Roux-en-Y gastric bypass. Conclusions and Relevance: Among patients with morbid obesity, there was no significant difference in excess BMI loss between laparoscopic sleeve gastrectomy and laparoscopic Roux-en-Y gastric bypass at 5 years of follow-up after surgery. Trial Registration: clinicaltrials.gov Identifier: NCT00356213.
RCT Entities:
Importance: Sleeve gastrectomy is increasingly used in the treatment of morbid obesity, but its long-term outcome vs the standard Roux-en-Y gastric bypass procedure is unknown. Objective: To determine whether there are differences between sleeve gastrectomy and Roux-en-Y gastric bypass in terms of weight loss, changes in comorbidities, increase in quality of life, and adverse events. Design, Setting, and Participants: The Swiss Multicenter Bypass or Sleeve Study (SM-BOSS), a 2-group randomized trial, was conducted from January 2007 until November 2011 (last follow-up in March 2017). Of 3971 morbidly obesepatients evaluated for bariatric surgery at 4 Swiss bariatric centers, 217 patients were enrolled and randomly assigned to sleeve gastrectomy or Roux-en-Y gastric bypass with a 5-year follow-up period. Interventions: Patients were randomly assigned to undergo laparoscopic sleeve gastrectomy (n = 107) or laparoscopic Roux-en-Y gastric bypass (n = 110). Main Outcomes and Measures: The primary end point was weight loss, expressed as percentage excess body mass index (BMI) loss. Exploratory end points were changes in comorbidities and adverse events. Results: Among the 217 patients (mean age, 45.5 years; 72% women; mean BMI, 43.9) 205 (94.5%) completed the trial. Excess BMI loss was not significantly different at 5 years: for sleeve gastrectomy, 61.1%, vs Roux-en-Y gastric bypass, 68.3% (absolute difference, -7.18%; 95% CI, -14.30% to -0.06%; P = .22 after adjustment for multiple comparisons). Gastric reflux remission was observed more frequently after Roux-en-Y gastric bypass (60.4%) than after sleeve gastrectomy (25.0%). Gastric reflux worsened (more symptoms or increase in therapy) more often after sleeve gastrectomy (31.8%) than after Roux-en-Y gastric bypass (6.3%). The number of patients with reoperations or interventions was 16/101 (15.8%) after sleeve gastrectomy and 23/104 (22.1%) after Roux-en-Y gastric bypass. Conclusions and Relevance: Among patients with morbid obesity, there was no significant difference in excess BMI loss between laparoscopic sleeve gastrectomy and laparoscopic Roux-en-Y gastric bypass at 5 years of follow-up after surgery. Trial Registration: clinicaltrials.gov Identifier: NCT00356213.
Authors: M Helmiö; M Victorzon; J Ovaska; M Leivonen; A Juuti; P Peromaa-Haavisto; P Nuutila; T Vahlberg; P Salminen Journal: Scand J Surg Date: 2014-02-12 Impact factor: 2.360
Authors: Francesco Rubino; David M Nathan; Robert H Eckel; Philip R Schauer; K George M M Alberti; Paul Z Zimmet; Stefano Del Prato; Linong Ji; Shaukat M Sadikot; William H Herman; Stephanie A Amiel; Lee M Kaplan; Gaspar Taroncher-Oldenburg; David E Cummings Journal: Surg Obes Relat Dis Date: 2016-07 Impact factor: 4.734
Authors: Sachin S Shenoy; Andrew Gilliam; Ahmed Mehanna; Venkatesh Kanakala; Gopinath Bussa; Talvinder Gill; Katherine Sanderson; Y K S Viswanath; Venkatesh Shanmugam Journal: Obes Surg Date: 2020-11 Impact factor: 4.129
Authors: Guilherme S Mazzini; Jad Khoraki; Matthew G Browning; Bernardo M Pessoa; Luke G Wolfe; Guilherme M Campos Journal: Obes Surg Date: 2020-03 Impact factor: 4.129
Authors: Valentin Mocanu; Krista Lai; Jerry T Dang; Noah J Switzer; Daniel W Birch; Geoff D C Ball; Shahzeer Karmali Journal: Obes Surg Date: 2021-02-06 Impact factor: 4.129
Authors: Ben Gys; Philip Plaeke; Bas Lamme; Thierry Lafullarde; Niels Komen; Anthony Beunis; Guy Hubens Journal: Obes Surg Date: 2019-09 Impact factor: 4.129